K. K. To, O. T. Tsang, W. S. Leung, A. R. Tam, T. C. Wu et al., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, issue.20, pp.30196-30197, 2020.

R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature, 2020.

J. A. Siordia, Epidemiology and clinical features of COVID-19: A review of current literature, J Clin Virol, vol.127, p.104357, 2020.

S. J. Migchelsen, D. L. Martin, K. Southisombath, P. Turyaguma, A. Heggen et al., Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies, PLoS Negl Trop Dis, vol.11, issue.1, p.5230, 2017.

, SARS-CoV-2 diagnostics: performance data. The Foundation for Innovative New Diagnostics (FIND)

L. Guo, L. Ren, and S. Yang, Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19), Clin Inf Dis, 2020.

N. Okba, M. A. Muller, and W. Li, SARS-CoV-2 specific antibody responses in COVID-19 patients, medRxiv, 2020.

F. Amanat, D. Stadlbauer, S. Strohmeier, T. Nguyen, V. Chromikova et al., A serological assay to detect SARS-CoV-2 seroconversion in humans, Nature Med, 2020.

A. T. Huang, B. Garcia-carreras, M. Hitchings, B. Yang, L. Katzelnick et al., A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease, medRxiv, 2020.

M. T. White, J. T. Griffin, and O. Akpogheneta, Dynamics of the antibody response to Plasmodium falciparum infection in African children, J Infect Dis, vol.210, pp.1115-1137, 2014.

P. F. Teunis, J. C. Van-eijkeren, W. F. De-graaf, A. B. Marinovi?, and M. E. Kretzschmar, Linking the seroresponse to infection to within-host heterogeneity in antibody production, Epidemics, vol.16, pp.33-39, 2016.

M. Andraud, O. Lejeune, and . Musoro, Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus, PLoS Comput Biol, vol.8, p.1002418, 2012.

W. C. Cao, W. Liu, P. H. Zhang, F. Zhang, and J. H. Richardus, Disappearance of antibodies to SARS-associated coronavirus after recovery, N Engl J Med, vol.357, issue.11, pp.1162-1165, 2007.

P. J. Diggle, Estimating prevalence using an imperfect test, Epi Res International, p.608719, 2011.

A. Gelman and B. Carpenter, Bayesian analysis of tests with unknown specificity and sensitivity. medRxiv, 2020.

, World Health Organisation. When and how to use assays for recent infection to estimate HIV incidence at a population level, WHO, pp.978-92, 2011.

S. Takahashi and B. Greenhouse, Rodriguez-Barraquer I. Are SARS-CoV-2 seroprevalence estimates biased? OSF Preprints, 2020.

V. Yman, M. T. White, M. Asghar, C. Sundling, K. Sondén et al., Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure, BMC Med, vol.17, issue.1, p.22, 2019.

Q. Long, H. Deng, and J. Chen, Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice, MedRxiv, 2020.


R. Lassaunière, A. Frische, Z. B. Harboe, A. Nielsen, A. Fomsgaard et al., Evaluation of nine commercial SARS-CoV-2 immunoassays, medRxiv, 2020.

J. E. Bryant, A. S. Azman, M. J. Ferrari, B. F. Arnold, M. F. Boni et al., Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward, Science Immunol, vol.5, p.47, 2020.

D. B. Larremore, B. K. Fosdick, K. M. Bubar, S. Zhang, S. M. Kissler et al., Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. medRxiv, 2020.

L. Grzelak, S. Temmam, C. Planchais, C. Demeret, C. Huon et al., SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors, medRxiv, 2020.

Q. X. Long, X. J. Tang, Q. L. Shi, Q. Li, H. J. Deng et al., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nature Med, 2020.

R. L. Prentice, Surrogate endpoints in clinical-trials-definition and operational criteria, Stat Med, vol.8, pp.431-471, 1989.

L. Qin, P. B. Gilbert, L. Corey, M. J. Mcelrath, and S. G. Self, A framework for assessing immunological correlates of protection in vaccine trials, J Infect Dis, vol.196, pp.1304-1316, 2007.

M. T. White, O. Idoko, S. Sow, A. Diallo, B. Kampmann et al., Antibody kinetics following vaccination with MenAfriVac and implications for the duration of protection: an analysis of serological data, Lancet Inf Dis, vol.19, issue.3, pp.327-336, 2019.